Ind-Swift Laboratories Limited — Board Meeting, 31-01-2026: Outcome of Board Meeting

Ind-Swift Laboratories' board meeting approved Q3 consolidated net profit of ₹9.54 Cr on ₹150.85 Cr revenue. Key leadership changes were approved: Navrattan Munjal as Chairman & WTD, Himanshu Jain as MD (Domestic), Sahil Munjal as MD (Global). Also, ₹48 Cr debentures were redeemed, yielding ₹61.29 Cr.